- Home
- BIOR vs NRXP Comparison
BIOR vs NRXP Comparison
Compare BIOR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOR
- NRXP
- Stock Information
- Founded
- BIOR 2010
- NRXP 2015
- Country
- BIOR United States
- NRXP United States
- Employees
- BIOR N/A
- NRXP N/A
- Industry
- BIOR Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- BIOR Health Care
- NRXP Health Care
- Exchange
- BIOR Nasdaq
- NRXP Nasdaq
- Market Cap
- BIOR 12.6M
- NRXP 14.8M
- IPO Year
- BIOR 2020
- NRXP N/A
- Fundamental
- Price
- BIOR $2.12
- NRXP $1.19
- Analyst Decision
- BIOR Strong Buy
- NRXP Strong Buy
- Analyst Count
- BIOR 1
- NRXP 3
- Target Price
- BIOR $150.00
- NRXP $31.33
- AVG Volume (30 Days)
- BIOR 121.2K
- NRXP 158.2K
- Earning Date
- BIOR 11-14-2024
- NRXP 11-14-2024
- Dividend Yield
- BIOR N/A
- NRXP N/A
- EPS Growth
- BIOR N/A
- NRXP N/A
- EPS
- BIOR N/A
- NRXP N/A
- Revenue
- BIOR $892,000.00
- NRXP N/A
- Revenue This Year
- BIOR $32,550.00
- NRXP N/A
- Revenue Next Year
- BIOR $95.48
- NRXP N/A
- P/E Ratio
- BIOR N/A
- NRXP N/A
- Revenue Growth
- BIOR 4855.56
- NRXP N/A
- 52 Week Low
- BIOR $2.03
- NRXP $1.10
- 52 Week High
- BIOR $19.90
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- BIOR 25.71
- NRXP 37.26
- Support Level
- BIOR $2.44
- NRXP $1.12
- Resistance Level
- BIOR $3.10
- NRXP $1.30
- Average True Range (ATR)
- BIOR 0.36
- NRXP 0.10
- MACD
- BIOR -0.03
- NRXP 0.00
- Stochastic Oscillator
- BIOR 4.95
- NRXP 21.21
About BIOR Biora Therapeutics Inc.
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.